Utilization of Beta-blockers Among the Pediatric Population in the United States: A Study in the FDA’s Sentinel System from 2008 to 2022

Beta-blockers are only approved for two pediatric indications in the United States (i.e., hypertension and hemangioma), but are commonly used for a variety of off-label conditions. Little is known about the magnitude and patterns of their use in the pediatric population.
 

This poster examines utilization patterns of beta-blockers among the pediatric population in the United States. It was presented at the 39th International Conference on Pharmacoepidemiology and Therapeutic Risk Management.